| 名稱 | TFG-NTRK1/BaF3 |
| 型號 | CBP73193 |
| 報價 |  |
| 特點 | TFG-NTRK1/BaF3,母細胞：BaF3，凍存條件：90% FBS+10% DMSO； |
產品搜索
相關文章
聯(lián)系我們
聯(lián)系人：蔣經理
電話：4008750250
號碼：
手機：18066071954
地址：南京市棲霞區(qū)緯地路9號
Email： zhangxiangwen@cobioer.com
電話：4008750250
號碼：
手機：18066071954
地址：南京市棲霞區(qū)緯地路9號
Email： zhangxiangwen@cobioer.com
產品展示 / PRODUCTS
藥靶細胞株 > kinase激酶細胞株 > CBP73193TFG-NTRK1/BaF3
- 詳細內容
CBP73193 | |
| I. Introduction | |
Cell Line Name： | TFG-NTRK1/BaF3 |
Host Cell: | Ba/F3 |
| Stability: | 16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
Application: | Anti-proliferation assay and PD assay |
Freeze Medium: | 90% FBS+10% DMSO |
Complete Culture Medium: | RPMI-1640+10% FBS+1 ug/ml puromycin |
Mycoplasma Status: | Negative |
| II.Background | |
NTRK1 rearrangements involve the kinase domain of the NTRK1 gene which includes 17 exons located on chromosome 1q21-22 (Alberti et al. 2003). The frequency of NTRK1 fusions in patients with adenocarcinoma histology is 3.3% of cases (3 out of 91 patients; Vaishnavi et al. 2013). a In preclinical studies, cell lines expressing MPRIP-NTRK1 or CD74-NTRK1 were inhibited by ARRY-470, a TRKA/B/C inhibitor (Vaishnavi et al. 2013). b In preclinical studies, cell lines expressing MPRIP-NTRK1 or CD74-NTRK1 were inhibited by lestaurtinib, a FLT3/TRKA inhibitor (Vaishnavi et al. 2013). c A patient with non-small cell lung cancer harboring an MPRIP-NTRK1 fusion mutation was treated with crizotinib, which has activity against TRKA in addition to ALK, MET and ROS1 (Vaishnavi et al. 2013). The patient demonstrated a small radiographic decrease in tumor size but experienced disease progression after three months (Vaishnavi et al. 2013) | |
| III. Representative Data | |
1. WB of TFG-NTRK1/BaF3 expression | |
| |
2. Anti-proliferation assay | |
| |
Figure 2. Anti-proliferation assay of two reference compounds on the TFG-NTRK1/BaF3 Stable Cell Line | |
